Association of Ureaplasma infection pattern and azithromycin treatment effect with bronchopulmonary dysplasia in Ureaplasma positive infants: a cohort study

Chen, Xueyu; Huang, Xuemei; Lin, Yanqing; Lin, Bingchun; Yang, Chunyu; Huang, Zhifeng; Yang, Chuanzhong

doi:10.1186/s12890-023-02522-4

Cited by 4 publications

(1 citation statement)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Treatment could also be considered if there is also high clinical and radiographic suspicion of active infection. 223 Early Course: First Week of Life -Fluid Management and Nutritional Strategies Subgroup analysis of the multicenter Preterm Erythropoietin Neuroprotection Trial (PENUT) revealed that higher peak fluid balance (calculated by percentage change in weight from BW) was associated with increased risk for IMV on DOL 14 and in the combined outcome for BPD and mortality. 109 Every 10% increase in peak fluid balance was associated with 103% increased odds of receipt of IMV on DOL 14 (aOR: 2.03, 95% CI: 1.64-2.51).…”

Section: Early Course: First Week Of Life -Judicious Use Of Antimicro...mentioning

confidence: 99%

Prevalence, Prevention and Management of Bronchopulmonary Dysplasia

Gilfillan,

Mejia,

Bhandari

2024

RRN

View full text Add to dashboard Cite

Bronchopulmonary dysplasia (BPD) is a complex pulmonary condition that arises in preterm infants secondary to a constellation of adverse exposures contributing to impaired lung development and repair. In many developed countries, the incidence of BPD continues to rise despite the increasing use of evidence-based therapies and efforts to minimize adverse post-natal exposures. Refinement of perinatal care practices that reduce mortality in the most immature infants is likely contributing to this trend; however, a growing population of survivors with respiratory morbidity significantly burdens individuals and health-care systems. Racial and socioeconomic disparities also result in unequal distribution of morbidity within society. In this review, we will outline trends in the incidence of BPD over the last decade and review important risk factors for adverse pulmonary outcomes. The consequences of BPD for long-term health will be described, followed by a comprehensive summary of evidence-based therapies and potential future treatments that can be applied to reduce the incidence, and the prevalence of BPD.

show abstract

Section: Early Course: First Week Of Life -Judicious Use Of Antimicro...mentioning

confidence: 99%

Prevalence, Prevention and Management of Bronchopulmonary Dysplasia

Gilfillan,

Mejia,

Bhandari

2024

RRN

View full text Add to dashboard Cite

show abstract

Association between Ureaplasma colonization and bronchopulmonary dysplasia defined by different criteria in very low birth weight infants: A retrospective cohort study

Ji,

Gu,

Bao

et al. 2024

Pediatric Pulmonology

View full text Add to dashboard Cite

ObjectiveTo study the association between Ureaplasma colonization and bronchopulmonary dysplasia (BPD) with different definitions in very low birth weight (VLBW) infants.MethodsA retrospective cohort study was performed with VLBW infants admitted from January 2019 to October 2021. Neonates with a positive respiratory tract Ureaplasma culture were included in the study group. Control group infants, matched for gestational age (±1 week), birth weight (±100 g), and birth year, had a negative respiratory tract Ureaplasma culture during the same period. The primary outcomes included the incidence and severity of BPD, defined by various criteria.ResultsThe study included 302 neonates (151 in the study group and 151 in the control group). After adjusting for confounders, Ureaplasma colonization was not associated with BPD as defined by the National Institutes of Health (NIH) in 2001 (adjusted odds ratio [aOR]: 0.820, 95% confidence interval [CI]: 0.362–1.860, p = .635). However, it was associated with BPD as defined by the NIH in 2018 (aOR: 2.490, 95% CI: 1.128–5.497, p = .024) and the Neonatal Research Network (NRN) in 2019 (aOR: 2.352, 95% CI: 1.077–5.134, p = .032). Additionally, VLBW infants with Ureaplasma colonization had a higher risk of moderate‐severe BPD according to the NIH 2001 (aOR: 2.352, 95% CI: 1.077–5.134, p = .032), NIH 2018 (aOR: 6.339, 95% CI: 1.686–23.836, p = .006), and NRN 2019 definitions (aOR: 3.542, 95% CI: 1.267–9.904, p = .016).ConclusionsUreaplasma colonization is not associated with BPD by the NIH 2001 definition, but is associated with an increased incidence by the NIH 2018 or NRN 2019 definitions.

show abstract

Azithromycin for Preventing Bronchopulmonary Dysplasia in Extremely Preterm Infants: A Cohort Study

Zeng,

Huang,

Wang

et al. 2024

Pediatric Pulmonology

View full text Add to dashboard Cite

ObjectivesTo test the effect of azithromycin in reducing bronchopulmonary dysplasia (BPD) risk in extremely preterm infants (EPI) without pulmonary infection.Study DesignA retrospective cohort study was performed in EPI in a tertiary unit from September 2018 to September 2022. Since only Ureaplasma species positive infants were treated with azithromycin, we included infants without Ureaplasma species (no azithromycin treatment) and those diagnosed with Ureaplasma species colonization (azithromycin treatment) in the study, while infants with Ureaplasma species pneumonia were excluded. The primary outcome was grade II+ BPD, defined as BPD of grade II or higher according to the updated NICHD criteria (2018). Multiple logistic regression analysis was used to identify the independent association between grade II+ BPD and azithromycin treatment.ResultsA total of 237 EPIs were included in the current study, of which 202 infants were classified as no azithromycin treatment (Ureaplasma species negative) and 35 infants were classified as azithromycin treatment (Ureaplasma species colonization). Clinical characteristics were similar between groups. Infants treated with azithromycin had a significantly lower rate of grade II+ BPD (8.6% vs. 31.2%, p = 0.006), and shorter duration of invasive ventilation (0 vs. 3 days, p = 0.045) compared to untreated ones. After adjusting for confounders, azithromycin treatment was significantly associated with reduced risk of grade II+ BPD in the whole cohort (odd ratio [OR] 0.211, 95% CI: 0.056, 0.786, p = 0.020], and infants absent of other pulmonary infection (OR 0.115, 95% CI: 0.014, 0.979, p = 0.048).ConclusionAzithromycin is associated with a reduced risk of grade II+ BPD in EPIs, likely due to its anti‐inflammatory effect.

show abstract

Association of Ureaplasma infection pattern and azithromycin treatment effect with bronchopulmonary dysplasia in Ureaplasma positive infants: a cohort study

Cited by 4 publications

References 26 publications

Prevalence, Prevention and Management of Bronchopulmonary Dysplasia

Prevalence, Prevention and Management of Bronchopulmonary Dysplasia

Association between Ureaplasma colonization and bronchopulmonary dysplasia defined by different criteria in very low birth weight infants: A retrospective cohort study

Azithromycin for Preventing Bronchopulmonary Dysplasia in Extremely Preterm Infants: A Cohort Study

Contact Info

Product

Resources

About